1. Scrip
  2. >>Business

Fosun’s IPO Plan For India’s Gland Hits Multiple Targets

Need For Funds, Military Tensions With India In Backdrop

 
• By Vibha Ravi

With a proposed IPO, Gland Pharma’s parent company, Fosun Pharma, hopes to raise funds for its injectables business and possibly its COVID-19 vaccine. The move will also cut Chinese ownership against a backdrop of shaky relations between India and China. As investors warm up to pharma stocks, the timing seems right.

Targets hit in the center by arrows
Bull's Eye For Fosun? • Source: Shutterstock

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd.’s plan for an initial public offering (IPO) of its Indian subsidiary, Gland Pharma, aims to achieve multiple objectives. Not only will it raise funds for Fosun’s fast-growing injectables business and possibly for a COVID-19 vaccine in the works with BioNTech SE, it will also cut Fosun’s ownership in the Indian company at a time when relations between the two countries are not at their best.

While the issue date, price band and other details have not yet been disclosed yet, local media reports indicate the IPO aims to raise around INR50-60bn ($663m-796m) though the size may change closer to the launch

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 
• By Andrew McConaghie

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.

Executives On The Move: Altesa BioSciences Acquires Chief Medical Officer From GSK, Scholar Rock Gets A New CEO, And More

Recent moves in the industry include C-suite changes at Scholar Rock and Augustine Therapeutics, plus Contineum Therapeutics acquires chief medical officer from Gilead Sciences.

Dr Reddy’s Gears For Tariffs Scenario To Ensure No US Supply Disruption

 
• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.